Ralph M. Steinman, Ph.D.
Canadian immunologist and cell biologist at Rockefeller University
“ Discovery of the dendritic cell and its role in adaptive immunity”
The Nobel Prize in
Physiology or Medicine 2011 (Awarded Posthumously)
(January 14, 1943 – September 30, 2011)
PERSONALIZED MEDICINE PERSONALIZED MEDICINE
FRANCISCO S. CHUNG JR. PhD Co Director
Cellular Therapeutics Center Makati Medical Center
DISRUPTIVE TECHNOLOGY IN THE AGE OF PERSONALIZED MEDICINE
DISRUPTIVE TECHNOLOGY IN THE
AGE OF PERSONALIZED MEDICINE
Disclosure: Clinical data to be presented are in accordance to Helsinki Declaration
The World Medical Association (WMA) has developed the Declaration of Helsinki as a statement of ethical principles for medical research involving human subjects, including
research on identifiable human material and data.
International Ethical Guidelines for Biomedical Research Involving Human Subjects by World Health Organization (WHO) and Council for
International Organizations of Medical Sciences
(CIOMS)
“It’s far more important to know what person the disease has than what disease the person has.”
– Hippocrates
DEFINING PERSONALIZED MEDICINE
Early Examples of Personalized Medicine
• 1907: Reuben Ottenberg reports the first known blood compatibility test for transfusion using blood typing techniques and cross-matching
between donors and patients to prevent hemolytic transfusion reactions.
• 1956: The genetic basis for the selective toxicity of fava beans
(favism) and the antimalarial drug primaquine is discovered to be a
deficiency in the metabolic enzyme, glucose-6-phosphate dehydrogenase (G6PD).
• 1977: Cytochrome P450 2D6, a polymorphic metabolizing enzyme, is identified as the culprit for causing some patients to experience an
“overdose” or exaggeration of the duration and intensity of the effects of debrisoquine, a drug used for treating hypertension.
Megatrends Impacting the Entire Spectrum of Care
A modern health care system is on the horizon, demanding a paradigm shif
One Size Fits All
Fragmented, One-way Provider Centric
Centralized, Hospital Based Fragmented Specialized Procedure-based
Treating Sickness
APPROACH INFORMATION FLOW
FOCUS LOCATION TREATMENT REIMBURSEMENT
OBJECTIVE
Peronalized Medicine Integrated, Two Way Patient Centric
Decentralized Community-based Collaborative Shared Information
Outcomes-based
Preventing Sickness (Wellness)
Source: Frost & Sullivan
Four Essential Components for a Successful
Personalized Medicine : G.I.F.T Model
MOLECULAR DIAGNOSTICS ACROSS MEDICAL DISCIPLINES
CIRCULATING
TUMOR CELLS
ASSAY
ECONOMICS OF MOLECULAR DIAGNOSTICS
INTEGRATING MOLECULAR DIAGNOSTICS WITH
THERAPEUTICS
CHANGING TREATMENT PROTOCOLS IN CLINICAL
PRACTICE
MARKET DEVELOPMENTS FOR PERSONALIZED MEDICINE IN MOLECULAR DIAGNOSTIC TESTS
• Molecular diagnostics market has grown at double- digit pace, achieving an overall 14% CAGR
(Compound Annual Growth Rate) to meet increasing demand for personalized medicine as of 2015.
• Key areas of growth
a. Infectious diseases b. Oncology
c. Genetic testing
d. Blood banking
• Personalized Medicine promises more precise, efficient patient care.
• The infrastructure of a successful personalized medicine center should have FOUR ESSENTIAL COMPONENTS:
1. Genomic/molecular data acquisition and storage,
2. Integration of genomic diagnostic testing and targeted imaging,
3. Research focused on functional genomic targets, and
4. Development and informed use of targeted therapies of actionable genes.
• Moving forward, clear and centralized consensus on actionable genes is needed.
CONCLUSIONS
• http://www.fda.gov/downloads/ScienceResearch/SpecialTopics/PersonalizedMedicine/UCM3 72421.pdf
• http://www.asiabiotech.com/17/1712/17120028x.html
• http://medtechevents.blogspot.com/2016_01_01_archive.html
• http://alliancerm.org/page/clinical-trials-products
• http://www.cellr4.org/article/856
• Constance, J.A. (2010). The future of molecular diagnostics- Innovative technologies driving market opportunities in personalized medicine. Business Insights Ltd.
